CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential

被引:129
作者
Deaglio, Silvia
Vaisitti, Tiziana
Aydin, Sernra
Bergui, Luciana
D'Arena, Giovanni
Bonello, Lisa
Omede, Paola
Scatolini, Maria
Jaksic, Ozren
Chiorino, Giovanna
Efremov, Dimitar
Malavasil, Fabio
机构
[1] Univ Turin, Sch Med, Dept Genet Biol & Biochem, Turin, Italy
[2] Univ Turin, Sch Med, Res Ctr Expt Med, Turin, Italy
[3] Univ Turin, Sch Med, Dept Med & Expt Oncol, Turin, Italy
[4] Fondazione Pascale, Ricovero Cura Carattere Sci, Naples, Italy
[5] Fondo Edo Tempia, Biella, Italy
[6] Univ Zagreb, Merkur Univ Hosp, Dept Hematol, HR-10002 Zagreb, Croatia
[7] Int Ctr Genet Engn & Biotechnol, Monterotondo, Italy
[8] Consiglio Nazionale Richerche, Rome, Italy
关键词
D O I
10.1182/blood-2007-06-094029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our interest in chronic lymphocytic leukemia (CLL) derives primarily from the exploitation of human diseases as strategic models for defining the in vivo biological roles of CD38. Using this model, we showed that CD38 triggers robust proliferation/survival signals modulated through the interactions with the CD31 ligand expressed by nurse-like cells and by the stromal/endothelial components. By analyzing a cohort of 56 patients with clinically and molecularly characterized CLL, we show that (1) patients with CD38(+)/ZAP-70(+) are characterized by enhanced migration toward Stromal derived factor-la (SDF-1 alpha)/CXCL12; (2) CD38 ligation leads to tyrosine phosphorylation of ZAP-70, showing that these markers are functionally linked; (3) ZAP-70 represents a limiting factor for the CD38 pathway in the CLL context, as shown by studying CD38-mediated signal transduction in 26 molecularly characterized patients; and (4) the CLL subgroup of patients defined on the basis of migratory potential is marked by a specific genetic signature, with a significant number of differentially expressed genes being involved in cell-cell interactions and movement. Altogether, the results of this work provide biological evidence for why the combined analysis of CD38 and ZAP-70 expression as determined in several clinical trials results in more dependable identification of patients with CLL who have aggressive disease.
引用
收藏
页码:4012 / 4021
页数:10
相关论文
empty
未找到相关数据